Long-term Durability of Narrowband Ultraviolet B-induced Repigmentation in Non-segmental Vitiligo: A Retrospective Study
DOI:
https://doi.org/10.2340/actadv.v105.43690Keywords:
Vitiligo, narrowband ultraviolet B phototherapy, durability of significant repigmentationAbstract
Narrowband ultraviolet B (NB-UVB) phototherapy is a well-established vitiligo treatment. However, limited data exist on the long-term effects of NB-UVB-induced repigmentation. This study evaluated the long-term durability of repigmentation achieved through NB-UVB phototherapy for up to 1 year in 176 patients with non-segmental vitiligo. Demographic and clinical variables, including age, gender, skin phototype, body site involvement, treatment duration, cumulative radiation dose, and clinically significant repigmentation response, were collected. Clinically significant repigmentation was defined as ≥ 50% repigmentation of vitiligo-affected areas, while a durable response was repigmentation lasting ≥ 6 months post-treatment. Of the 176 patients, 80 (45%) achieved clinically significant repigmentation, with the highest success rates observed in the face and neck region (53%). Among responders, 76 (95%) patients maintained their response for ≥ 6 months post-treatment discontinuation, and 47 (59%) sustained repigmentation for > 72 months. Additionally, ≥ 50% repigmentation, longer treatment duration (> 18 months), and higher cumulative radiation dose (> 356 J/cm²) were associated with a durable repigmentation response. NB-UVB phototherapy provides lasting repigmentation in non-segmental vitiligo, with many patients maintaining results for > 6 years. Clinically significant response post-NB-UVB phototherapy, prolonged treatment duration, and cumulative radiation dose are key factors associated with long-term repigmentation.
Downloads
References
Monem El Mofty A. A preliminary clinical report on the treatment of leucodermia with Ammi majus Linn. J Egypt Med Assoc 1948; 31: 651–665.
Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch Dermatol 1997; 133: 1525–1528. DOI: https://doi.org/10.1001/archderm.1997.03890480045006
Parsad D, Kanwar AJ, Kumar B. Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo. J Eur Acad Dermatol Venereol 2006; 20: 175–177. DOI: https://doi.org/10.1111/j.1468-3083.2006.01413.x
Natta R, Somsak T, Wisuttida T, Laor L. Narrowband ultraviolet B radiation therapy for recalcitrant vitiligo in Asians. J Am Acad Dermatol 2003; 49: 473–476. DOI: https://doi.org/10.1067/S0190-9622(03)01484-1
Kanwar AJ, Dogra S, Parsad D, Kumar B. Narrow-band UVB for the treatment of vitiligo: an emerging effective and well-tolerated therapy. Int J Dermatol 2005; 44: 57–60. DOI: https://doi.org/10.1111/j.1365-4632.2004.02329.x
Bae JM, Jung HM, Hong BY, Lee JH, Choi WJ, Lee JH, et al. Phototherapy for vitiligo: a systematic review and meta-analysis. JAMA Dermatol 2017; 153: 666–674. DOI: https://doi.org/10.1001/jamadermatol.2017.0002
Yones SS, Palmer RA, Garibaldinos TM, Hawk JL. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs narrowband-UV-B therapy. Arch Dermatol 2007; 143: 578–584. DOI: https://doi.org/10.1001/archderm.143.5.578
Hamzavi I, Rosmarin D, Harris JE, Pandya AG, Lebwohl M, Gottlieb AB, et al. Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: descriptive subgroup analyses from a phase 2, randomized, double-blind trial. J Am Acad Dermatol 2022; 86: 1398–1401. DOI: https://doi.org/10.1016/j.jaad.2021.05.047
Hwang JR, Driscoll MS. Review of ruxolitinib for treatment of non-segmental vitiligo. Ann Pharmacother 2023; 57: 948–955. DOI: https://doi.org/10.1177/10600280221143748
Nordlund JJ. Nonmelanoma skin cancer in vitiligo patients. J Am Acad Dermatol 2009; 61: 1080–1081. DOI: https://doi.org/10.1016/j.jaad.2009.06.072
Cabrera R, Hojman L, Recule F, Sepulveda R, Delgado I. Predictive model for response rate to narrowband ultraviolet B phototherapy in vitiligo: a retrospective cohort study of 579 patients. Acta Derm Venereol 2018; 98: 416–420. DOI: https://doi.org/10.2340/00015555-2889
Kanwar AJ, Dogra S. Narrow-band UVB for the treatment of generalized vitiligo in children. Clin Exp Dermatol 2005; 30: 332–336. DOI: https://doi.org/10.1111/j.1365-2230.2005.01837.x
Sitek JC, Loeb M, Ronnevig JR. Narrowband UVB therapy for vitiligo: does the repigmentation last? J Eur Acad Dermatol Venereol 2007; 21: 891–896. DOI: https://doi.org/10.1111/j.1468-3083.2007.01980.x
Nicolaidou E, Antoniou C, Stratigos AJ, Stefanaki C, Katsambas AD. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J Am Acad Dermatol 2007; 56: 274–278. DOI: https://doi.org/10.1016/j.jaad.2006.09.004
Silpa-Archa N, Weerasubpong P, Junsuwan N, Yothachai P, Supapueng O, Wongpraparut C. Treatment outcome and persistence of repigmentation from narrow-band ultraviolet B phototherapy in vitiligo. J Dermatolog Treat 2019; 30: 691–696. DOI: https://doi.org/10.1080/09546634.2018.1544409
Kishan Kumar YH, Rao GR, Gopal KV, Shanti G, Rao KV. Evaluation of narrow-band UVB phototherapy in 150 patients with vitiligo. Indian J Dermatol Venereol Leprol 2009; 75: 162–166. DOI: https://doi.org/10.4103/0378-6323.48662
Sherman S, Duskin-Bitan H, Agiv T, Bar D, Marom-Haham L, Levi A et al. Bidirectional association between vitiligo and melasma: a large-scale population-based study. Indian J Dermatol Venereol Leprol 2025, Jul 4. [Onlone ahead of print] DOI: https://doi.org/10.25259/IJDVL_1828_2024
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Riad Kassem, Ilya Vaynshteyn, Aviv Barzilai, Assaf Handelsman, Alon Scope, Moshe Schaffer, Sharon Baum, Felix Pavlotsky
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
